Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies

  • Jianming Ying
  • , Zifen Gao
  • , Hongyu Li
  • , Gopesh Srivastava
  • , Paul G. Murray
  • , Hwee Koon Goh
  • , Chai Yen Lim
  • , Yajun Wang
  • , Teresa Marafioti
  • , David Y. Mason
  • , Richard F. Ambinder
  • , Anthony T.C. Chan
  • , Qian Tao

Research output: Contribution to journalArticlepeer-review

Abstract

Epigenetic silencing of tumour suppressor genes (TSG) inactivates TSG functions. Previously, we identified PCDH10 as a methylated TSG in carcinomas. Here, we detected its frequent silencing and methylation in lymphoma cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell lymphoma and 1/3 of leukaemia cell lines, and in primary tumours but not in normal peripheral blood mononuclear cells or lymph nodes. PCDH10 silencing could be reversed by demethylation with 5-aza-2′- deoxycytidine. Methylation was further detected in 14% of Hodgkin lymphoma sera. Thus, PCDH10 methylation is frequently involved in lymphomagenesis and could serve as a tumour-specific biomarker.

Original languageEnglish
Pages (from-to)829-832
Number of pages4
JournalBritish Journal of Haematology
Volume136
Issue number6
DOIs
Publication statusPublished - Mar 2007
Externally publishedYes

Keywords

  • Biomarker
  • Lymphoma
  • Methylation
  • PCDH10
  • Tumour suppressor gene

Fingerprint

Dive into the research topics of 'Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies'. Together they form a unique fingerprint.

Cite this